Cancers, Vol. 11, Pages 1352: Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma

Cancers, Vol. 11, Pages 1352: Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma Cancers doi: 10.3390/cancers11091352 Authors: Reetobrata Basu Prateek Kulkarni Yanrong Qian Christopher Walsh Pranay Arora Emily Davis Silvana Duran-Ortiz Kevin Funk Diego Ibarra Colin Kruse Samuel Mathes Todd McHugh Alison Brittain Darlene E. Berryman Edward O. List Shigeru Okada John J. Kopchick Growth hormone (GH) facilitates therapy resistance in the cancers of breast, colon, endometrium, and melanoma. The GH-stimulated pathways responsible for this resistance were identified as suppression of apoptosis, induction of epithelial-to-mesenchymal transition (EMT), and upregulated drug efflux by increased expression of ATP-binding cassette containing multidrug efflux pumps (ABC-transporters). In extremely drug-resistant melanoma, ABC-transporters have also been reported to mediate drug sequestration in intracellular melanosomes, thereby reducing drug efficacy. Melanocyte-inducing transcription factor (MITF) is the master regulator of melanocyte and melanoma cell fate as well as the melanosomal machinery. MITF targets such as the oncogene MET, as well as MITF-mediated processes such as resistance to radiation therapy, are both known to be upregulated by GH. Therefore, we chose to query the direct effects of GH on MITF expression and activity toward...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research